IF CLR01 (molecular tweezer; 40–200 µg/kg intravenous bolus, dose-escalated across cohorts) is administered systemically to aged, naturally polypathological C57BL/6J mice (18–22 months, both sexes) immediately following spatially targeted, MRI-guided focused ultrasound (FUS; 1.0–1.5 MHz, 0.35–0.50 MPa peak negative pressure, lipid-shell microbubble co-injection, targeting hippocampus and substantia nigra bilaterally), with treatment cycles repeated weekly for 8 weeks,

THEN a statistically significant reduction (≥40% compared to systemic CLR01 alone and ≥60% compared to vehicle) in the parenchymal burden of all three co-occurring amyloid species — Aβ plaques, hyperphosphorylated tau aggregates, and α-synuclein inclusions — will be observed by quantitative immunofluorescence and ELISA on hippocampal and nigral tissue, accompanied by measurable functional rescue in spatial memory (Morris water maze) and motor coordination (beam traversal), compared to age-matched controls receiving either systemic CLR01 alone, FUS alone, or vehicle,

BECAUSE the following mechanistic chain operates:

1. Aged C57BL/6J mice accumulate endogenous Aβ oligomers, hyperphosphorylated tau, and α-synuclein inclusions in hippocampus and substantia nigra as a function of chronological aging, constituting genuinely accumulated pan-amyloid damage requiring active repair rather than slowed accrual (CLR01 broad-spectrum inhibition, as described in Sinha et al., J. Am. Chem. Soc., 2011, cited in evidence set).

2. CLR01 passively crosses the BBB at only ~2% of plasma concentrations under conventional systemic dosing, producing subtherapeutic parenchymal levels that are insufficient to disaggregate already-deposited, structurally stable amyloid assemblies in aged brain (brain uptake pharmacokinetics, cited in Attar et al., Brain, 2012, and BBB permeability limitation noted in evidence set).

3. FUS at 1.0–1.5 MHz combined with intravenous lipid-shell microbubbles (e.g., Definity) induces stable cavitation-mediated mechanical disruption of endothelial tight junction proteins (claudin-5, occludin), transiently and reversibly opening paracellular routes in targeted brain regions with millimeter-scale spatial precision (Sheikov et al., 2008; Choi et al., 2011, cited in evidence set).

4. FUS-mediated BBB opening, validated to deliver agents ranging from small chemotherapeutics to immunoglobulins (~150 kDa) — far exceeding CLR01's molecular weight (~722 Da) — will increase local parenchymal CLR01 concentration by an estimated several-fold over passive delivery alone, reaching the stoichiometric threshold required for disaggregation of pre-formed oligomers and early fibrils (FUS delivery precedent from evidence set; Leinenga et al., Alzheimer's Research & Therapy, cited in evidence set).

5. At elevated local concentrations, CLR01 engages exposed lysine residues in the disordered regions of already-deposited Aβ (Lys16, Lys28), tau (multiple Lys residues in KXGS motifs), and α-s...

SENS category: GlycoSENS